Partnering & deal-making

Challenge: A pharmaceutical client asked Alacrita to assess a early-stage biotech company developing an orally-available agent for treating various autoimmune conditions. The pharma company was...

Challenge: A pharmaceutical company was actively searching for strategic partnering opportunities to expand its pipeline and had commissioned Alacrita to conduct a comprehensive pre-due diligence...

Challenge: A pharmaceutical company with an established gene-therapy franchise wanted to expand its oncology pipeline through external licensing. Among several options, the deal team had identified...

Challenge: A generalist investment fund with limited experience in the pharmaceutical sector was evaluating a co-investment opportunity in an early-stage therapeutic project targeting novel...

Project Challenge: A European biotech company was developing next-generation ADC payloads with at least as good intracellular cytotoxicity properties as other payloads used in ADCs, but with a much...

Project Challenge: Our client was a company on which we had conducted due diligence for an investor approached us for support with a potential deal with an AI discovery company. The concept was to...

Challenge: A medical device company has developed a nebulizer system for pulmonary delivery that can produce droplets below 1.5µm diameter. Initial clinical evaluations of demonstrator compounds used...

Challenge: A biotech company focusing in fibrosis and autoimmunity was planning a reverse takeover transaction with a listed entity and required support in formulating its proxy statement (investor...

Challenge A company was developing a unique dengue vaccine which it planned to out-license to a Big Pharma partner. Alacrita was commissioned to provide business development support to identify a...

Challenge Our client, a mid-cap research-based pharmaceutical company, had enjoyed striking success with a rare disease product which had different market dynamics to the bulk of the company's...

Challenge A biotech company focused on developing therapeutics for oncology indications was looking to contract a clinical consultant to support their in-house team in presenting its technology and...

Challenge: An investor group was facing its first potential deal in the pharmaceuticals sector. It had pre-negotiated a deal with a group that had invented an approach to treating...